At CMC Pharma, our mission is to advance the development and delivery of medical countermeasures that protect civilians and military personnel from chemical, biological, radiological, and nuclear (CBRN) threats. We achieve this by:
Our work with these consortia, along with multiple DoD contracts—both as a prime and subcontractor—demonstrates our ability to collaborate effectively across public and private sectors to identify and advance new countermeasures.
By partnering with CMC, government and industry teams can leverage our scientific, operational, and regulatory expertise to accelerate programs that improve survivability, reduce logistical burden, and extend the shelf life of critical therapies.
Our integrated approach ensures data generated in the lab is directly aligned with regulatory expectations, accelerating program progression without costly rework.
CMC Pharma differentiates itself by collaborating with both industry and government partners and can collaborate as both a prime and subcontractor, providing
This approach ensures that MCM programs progress efficiently, safely, and strategically, giving the government and industry partners confidence that their therapies will be ready when needed.
CMC Pharma is committed to advancing medical countermeasures that protect civilians and warfighters, reduce logistical burden, and modernize critical therapies. By integrating development, manufacturing, and regulatory guidance, we provide a single, trusted partner for complex, high-stakes programs. Partner with us to de-risk MCM programs, accelerate timelines, and deliver solutions that enhance readiness and survivability.
Whether you need to develop robust analytical methods or require routine testing. Contact CMC Pharma to learn how we can help you advance your development program.
Send us a message or give us a call at 440-485-1734.